|
Most recently serving as Managing Director of Lilly Ventures, Eli Lilly’s $175 million venture capital fund, Mr. Colangelo joins Oscient with over a decade of pharmaceutical experience. During his strategy and business development career at Lilly, he established himself as an integral component of several cross-functional initiatives aimed at maximizing product launches and successes in the Diabetes and Growth Disorders Products group. Mr. Colangelo serves on the Board of Trustees for the National Childhood Cancer Foundation and has served as a member of the board of directors of several private healthcare companies. Mr. Colangelo began his career as a practicing attorney and is a graduate of the Duke University School of Law. He received his bachelor's degree from the State University of New York at Buffalo, where he graduated magna cum laude.
| 